Advaxis shares jump on improved survival data from prostate cancer drug

Ayala Pharmaceuticals

07/10/2019 14:09

** Drug developer's shares  ADXS.O  rise 12% to 37 cents
premarket     
    ** Company says its experimental cancer drug ADXS-PSA in
combination with Merck and Co's  MRK.N  Keytruda extended
patients lives for a median of 33.6 months, higher than
previously reported 21.1 months  urn:newsml:reuters.com:*:nBw2HDM9Ra
    ** The combination was tested in an early-stage study of 37
patients with a type of prostate cancer; company is also testing
ADXS-PSA as a monotherapy
    ** Company says it is assessing a potential new study 
    ** Up to Friday's close, stock had fallen ~88% YTD

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208;))